ViewRay, Inc. designs, manufactures and markets MRIdian, the magnetic resonance imaging (MRI)-guided radiation therapy system to image and treat cancer patients simultaneously. The Company offers radiation therapy technology combined with magnetic resonance imaging. MRIdian integrates MRI technology, radiation delivery and the Company's software to locate, target and track the position and shape of soft-tissue tumors while radiation is delivered. MRIdian delivers radiation to the tumor accurately while delivering less radiation to healthy tissue. MRIdian provides real-time imaging that defines the targeted tumor from the surrounding soft tissue and other critical organs during radiation treatment. MRIdian allows physicians to record the level of radiation exposure that the tumor has received and adapt the prescription between fractions as needed.
Industry, Sector and Symbol
Industry Electromedical equipment
Sub-IndustryN/A
SectorMedical
Phone440-703-3210
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$80.96 million
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date8/2/2019 (Estimated)
OptionableOptionable
Viewray (NASDAQ:VRAY) Frequently Asked Questions
What is Viewray's stock symbol?
Viewray trades on the NASDAQ under the ticker symbol "VRAY."
How were Viewray's earnings last quarter?
Viewray Inc (NASDAQ:VRAY) announced its earnings results on Thursday, May, 2nd. The company reported ($0.34) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.22) by $0.12. The firm earned $20.30 million during the quarter, compared to analysts' expectations of $20.40 million. Viewray had a negative net margin of 139.82% and a negative return on equity of 71.16%. The business's revenue for the quarter was down 22.5% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.11) EPS. View Viewray's Earnings History.
When is Viewray's next earnings date?
What guidance has Viewray issued on next quarter's earnings?
Viewray issued an update on its FY 2019 earnings guidance on Thursday, March, 14th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $111-124 million, compared to the consensus revenue estimate of $124.33 million.
What price target have analysts set for VRAY?
9 Wall Street analysts have issued twelve-month price objectives for Viewray's stock. Their predictions range from $7.00 to $20.00. On average, they anticipate Viewray's share price to reach $13.1111 in the next twelve months. This suggests a possible upside of 52.5% from the stock's current price. View Analyst Price Targets for Viewray.
What is the consensus analysts' recommendation for Viewray?
9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Viewray in the last year. There are currently 1 hold rating and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Viewray.
What are Wall Street analysts saying about Viewray stock?
Here are some recent quotes from research analysts about Viewray stock:
- 1. Cantor Fitzgerald analysts commented, ": We reiterate our Overweight rating and $13 PT on VRAY. 1Q revenue of $20.3MM (-23%) was essentially in line with FactSet consensus of $20.4MM. We think the order beat is a better measure of the momentum of the business. VRAY received orders for seven MRIdians, two more than we were expecting for the second straight quarter. We think the order momentum is a direct result of the strategy that the new management team has implemented since taking over in July 2018. The finishing touches of management’s strategy are still coming together, but we think VRAY is positioned to capitalize on what we expect to be meaningful shift to adaptive therapy and MR linacs." (5/2/2019)
- 2. According to Zacks Investment Research, "ViewRay Inc. is a medical device company. The company develops advanced radiation therapy technology for the treatment of cancer. MRIdian system provides continuous soft-tissue imaging during treatment. ViewRay Inc. is headquartered in Oakwood Village, Ohio. " (3/20/2019)
- 3. Northland Securities analysts commented, "We now expect Elekta to begin a full commercial launch beginning Q1-19 (calendar)." (12/6/2018)
- 4. BTIG Research analysts commented, "PT to $14 from $10 VRAY preannounced 2Q rev and reported gross orders of $34.6M Friday coming in in line with consensus. Shares were probably pressured by GMs of ~0% due to one-time issues and expected cash use for the year being increased $10M. We continue to expect VRAY to require additional funding by 1H19. We like the new mgmt team’s track record both as operators and sellers of companies and expect an improvement in commercial execution. That said we felt the stock had overrun a bit to near $13 and would have moved to Neutral but with shares pulling back now still see them compelling. We are raising our out year PT to $14. While we still see VRAY as compelling we have learned quite a bit about potential new competition in MagnetTx (Private), whom we recently visited in Edmonton." (8/7/2018)
Has Viewray been receiving favorable news coverage?
Media coverage about VRAY stock has been trending somewhat positive recently, InfoTrie reports. The research firm identifies positive and negative media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Viewray earned a news impact score of 1.5 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the stock's share price in the next few days.
Are investors shorting Viewray?
Viewray saw a increase in short interest in the month of April. As of April 30th, there was short interest totalling 21,286,413 shares, an increase of 8.6% from the April 15th total of 19,600,819 shares. Based on an average daily volume of 770,602 shares, the short-interest ratio is presently 27.6 days. Approximately 30.0% of the shares of the company are short sold. View Viewray's Current Options Chain.
Who are some of Viewray's key competitors?
Some companies that are related to Viewray include CONMED (CNMD), NxStage Medical (NXTM), Natus Medical (BABY), AxoGen (AXGN), BioLife Solutions (BLFS), Semler Scientific (SMLR), Rockwell Medical (RMTI), Zynex (ZYXI), Cutera (CUTR), BioSig Technologies (BSGM), Stereotaxis (STXS), Fonar (FONR), Second Sight Medical Products (EYES), Edap Tms (EDAP) and electroCore (ECOR).
What other stocks do shareholders of Viewray own?
When did Viewray IPO?
(VRAY) raised $52 million in an IPO on the week of April 6th 2015. The company issued 4,000,000 shares at $12.00-$14.00 per share. Cowen and Company and Stifel acted as the underwriters for the IPO and BTIG and Brean Capital were co-managers.
Who are Viewray's major shareholders?
Viewray's stock is owned by a number of of retail and institutional investors. Top institutional investors include FMR LLC (9.53%), BlackRock Inc. (4.97%), Perceptive Advisors LLC (4.96%), Perceptive Advisors LLC (4.96%), Park West Asset Management LLC (4.19%) and Artisan Partners Limited Partnership (3.00%). Company insiders that own Viewray stock include Fmr Llc, International Ltd Fosun, James F Dempsey, Orbimed Advisors Llc, Scott William Drake and Shahriar Matin. View Institutional Ownership Trends for Viewray.
Which major investors are selling Viewray stock?
VRAY stock was sold by a variety of institutional investors in the last quarter, including Schonfeld Strategic Advisors LLC, FMR LLC, Frontier Capital Management Co. LLC, Goldman Sachs Group Inc., BlackRock Inc., Artisan Partners Limited Partnership, Pennsylvania Trust Co and Morgan Stanley. Company insiders that have sold Viewray company stock in the last year include Fmr Llc and Orbimed Advisors Llc. View Insider Buying and Selling for Viewray.
Which major investors are buying Viewray stock?
VRAY stock was acquired by a variety of institutional investors in the last quarter, including Greenvale Capital LLP, Park West Asset Management LLC, Perceptive Advisors LLC, Perceptive Advisors LLC, Assenagon Asset Management S.A., Granite Investment Partners LLC, Marshall Wace North America L.P. and Pier Capital LLC. Company insiders that have bought Viewray stock in the last two years include International Ltd Fosun, Scott William Drake and Shahriar Matin. View Insider Buying and Selling for Viewray.
How do I buy shares of Viewray?
Shares of VRAY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Viewray's stock price today?
One share of VRAY stock can currently be purchased for approximately $8.60.
How big of a company is Viewray?
Viewray has a market capitalization of $833.80 million and generates $80.96 million in revenue each year. The company earns $-76,400,000.00 in net income (profit) each year or ($0.98) on an earnings per share basis.
What is Viewray's official website?
How can I contact Viewray?
Viewray's mailing address is 2 THERMO FISHER WAY, OAKWOOD VILLAGE OH, 44146. The company can be reached via phone at 440-703-3210 or via email at [email protected]
MarketBeat Community Rating for Viewray (NASDAQ VRAY)
MarketBeat's community ratings are surveys of what our community members think about Viewray and other stocks. Vote "Outperform" if you believe VRAY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VRAY will underperform the S&P 500 over the long term. You may vote once every thirty days.
